R

Rhodri Davies

MRC Unit for Lifelong Health and Ageing

ORCID: 0000-0001-7630-7517

Publishes on Cardiac Imaging and Diagnostics, Cardiovascular Function and Risk Factors, Cardiomyopathy and Myosin Studies. 198 papers and 4.9k citations.

198Publications
4.9kTotal Citations

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

A minimum description length approach to statistical shape modeling
Rhodri Davies, Carole Twining, T.F. Cootes et al.|IEEE Transactions on Medical Imaging|2002
Cited by 571

We describe a method for automatically building statistical shape models from a training set of example boundaries/surfaces. These models show considerable promise as a basis for segmenting and interpreting images. One of the drawbacks of the approach is, however, the need to establish a set of dense correspondences between all members of a set of training shapes. Often this is achieved by locating a set of "landmarks" manually on each training image, which is time consuming and subjective in two dimensions and almost impossible in three dimensions. We describe how shape models can be built automatically by posing the correspondence problem as one of finding the parameterization for each shape in the training set. We select the set of parameterizations that build the "best" model. We define "best" as that which minimizes the description length of the training set, arguing that this leads to models with good compactness, specificity and generalization ability. We show how a set of shape parameterizations can be represented and manipulated in order to build a minimum description length model. Results are given for several different training sets of two-dimensional boundaries, showing that the proposed method constructs better models than other approaches including manual landmarking-the current gold standard. We also show that the method can be extended straightforwardly to three dimensions.

Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
Cited by 423Open Access

Abstract Individuals with potential exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not necessarily develop PCR or antibody positivity, suggesting that some individuals may clear subclinical infection before seroconversion. T cells can contribute to the rapid clearance of SARS-CoV-2 and other coronavirus infections 1–3 . Here we hypothesize that pre-existing memory T cell responses, with cross-protective potential against SARS-CoV-2 (refs. 4–11 ), would expand in vivo to support rapid viral control, aborting infection. We measured SARS-CoV-2-reactive T cells, including those against the early transcribed replication–transcription complex (RTC) 12,13 , in intensively monitored healthcare workers (HCWs) who tested repeatedly negative according to PCR, antibody binding and neutralization assays (seronegative HCWs (SN-HCWs)). SN-HCWs had stronger, more multispecific memory T cells compared with a cohort of unexposed individuals from before the pandemic (prepandemic cohort), and these cells were more frequently directed against the RTC than the structural-protein-dominated responses observed after detectable infection (matched concurrent cohort). SN-HCWs with the strongest RTC-specific T cells had an increase in IFI27 , a robust early innate signature of SARS-CoV-2 (ref. 14 ), suggesting abortive infection. RNA polymerase within RTC was the largest region of high sequence conservation across human seasonal coronaviruses (HCoV) and SARS-CoV-2 clades. RNA polymerase was preferentially targeted (among the regions tested) by T cells from prepandemic cohorts and SN-HCWs. RTC-epitope-specific T cells that cross-recognized HCoV variants were identified in SN-HCWs. Enriched pre-existing RNA-polymerase-specific T cells expanded in vivo to preferentially accumulate in the memory response after putative abortive compared to overt SARS-CoV-2 infection. Our data highlight RTC-specific T cells as targets for vaccines against endemic and emerging Coronaviridae .

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
Cited by 384Open Access

SARS-CoV-2 vaccine rollout has coincided with the spread of variants of concern. We investigated if single dose vaccination, with or without prior infection, confers cross protective immunity to variants. We analyzed T and B cell responses after first dose vaccination with the Pfizer/BioNTech mRNA vaccine BNT162b2 in healthcare workers (HCW) followed longitudinally, with or without prior Wuhan-Hu-1 SARS-CoV-2 infection. After one dose, individuals with prior infection showed enhanced T cell immunity, antibody secreting memory B cell response to spike and neutralizing antibodies effective against B.1.1.7 and B.1.351. By comparison, HCW receiving one vaccine dose without prior infection showed reduced immunity against variants. B.1.1.7 and B.1.351 spike mutations resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte antigen (HLA) polymorphisms. Single dose vaccination with BNT162b2 in the context of prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants.

Immune boosting by B.1.1.529 <b>(</b> Omicron) depends on previous SARS-CoV-2 exposure
Cited by 357Open Access

The Omicron, or Pango lineage B.1.1.529, variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and partial neutralizing antibody (nAb) escape. Vaccinated individuals show protection against severe disease, often attributed to primed cellular immunity. We investigated T and B cell immunity against B.1.1.529 in triple BioNTech BNT162b2 messenger RNA-vaccinated health care workers (HCWs) with different SARS-CoV-2 infection histories. B and T cell immunity against previous variants of concern was enhanced in triple-vaccinated individuals, but the magnitude of T and B cell responses against B.1.1.529 spike protein was reduced. Immune imprinting by infection with the earlier B.1.1.7 (Alpha) variant resulted in less durable binding antibody against B.1.1.529. Previously infection-naïve HCWs who became infected during the B.1.1.529 wave showed enhanced immunity against earlier variants but reduced nAb potency and T cell responses against B.1.1.529 itself. Previous Wuhan Hu-1 infection abrogated T cell recognition and any enhanced cross-reactive neutralizing immunity on infection with B.1.1.529.